兆科眼科：国家药监局受理环孢素眼用凝胶的新药上市申请

Core Viewpoint - The announcement indicates that the National Medical Products Administration of China has accepted the new drug application for cyclosporine eye gel, which is developed by the company for the treatment of moderate to severe dry eye disease [1] Group 1: Product Development - Cyclosporine eye gel is an innovative formulation developed by the company in China, specifically designed for treating moderate to severe dry eye disease [1] - The product is a patented hydrogel that has received international patent approval [1] Group 2: Clinical Trial Results - Phase II and Phase III clinical trial results demonstrate that cyclosporine eye gel shows good efficacy and safety [1] - The treatment can take effect quickly, with results potentially observable within two weeks [1] Group 3: Patient Compliance - The once-daily dosing regimen is expected to significantly improve patient adherence to the treatment and enhance their quality of life [1]